|
FRS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63302704692114E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.93020044392256E-11 |
| Normal-vs-Stage2 |
2.13099999999411E-05 |
| Normal-vs-Stage3 |
1.02070019103451E-10 |
| Normal-vs-Stage4 |
1.08669739873335E-11 |
| Stage1-vs-Stage2 |
6.115000E-01 |
| Stage1-vs-Stage3 |
1.071990E-01 |
| Stage1-vs-Stage4 |
9.457000E-03 |
| Stage2-vs-Stage3 |
1.754360E-01 |
| Stage2-vs-Stage4 |
4.295900E-02 |
| Stage3-vs-Stage4 |
2.826400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.31894495325469E-13 |
| Normal-vs-AfricanAmerican |
3.199700E-04 |
| Normal-vs-Asian |
4.51579995619511E-09 |
| Caucasian-vs-AfricanAmerican |
4.131600E-01 |
| Caucasian-vs-Asian |
8.414600E-01 |
| AfricanAmerican-vs-Asian |
3.315600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.12756503923129E-12 |
| Normal-vs-Female |
1.84474657771716E-12 |
| Male-vs-Female |
5.792600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.16010001394562E-09 |
| Normal-vs-Age(41-60Yrs) |
8.96980045794749E-10 |
| Normal-vs-Age(61-80Yrs) |
3.88920007310389E-11 |
| Normal-vs-Age(81-100Yrs) |
2.624300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.443400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.806200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.748600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.160800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.787600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.777000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.696370E-02 |
| Classical-VS-Follicular |
5.003800E-01 |
| Classical-VS-Other |
4.539600E-01 |
| Classical-VS-Normal |
1.75259999846133E-08 |
| Tall-VS-Follicular |
2.452000E-01 |
| Tall-VS-Other |
8.172200E-01 |
| Tall-VS-Normal |
3.70359964918521E-10 |
| Follicular-VS-Other |
7.621400E-01 |
| Follicular-VS-Normal |
1.96110000016958E-07 |
| Other-VS-Normal |
4.059000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.79856129989275E-13 |
| Normal-vs-N1 |
3.30359961608906E-10 |
| N0-vs-N1 |
4.886800E-01 |
|
|
